Diamyd kicks off recruitment campaign for Phase III in the US
Diamyd Medical AB (publ.) initiates the campaign for Phase III recruitment in
the US, by exhibiting at the ADA conference in San Francisco 6th - 10th of June
2008.
ADA, American Diabetes Association 68th Scientific Sessions, is the world's
largest exposition of diabetes-related products, services, and technology. More
than 13,000 top scientists, physicians and other health care professionals from
around the world will share cutting-edge research, treatment recommendations and
advances toward a cure for diabetes.
”The ADA conference is an excellent opportunity for us to meet and talk to
specialists in our field” says Elisabeth Lindner, President and CEO of Diamyd
Medical. “We are focusing on information to specialists about the Phase III
trials for the therapeutic diabetes vaccine Diamyd®, and we are also marketing
Diamyd Medical and strengthening our brand as a committed diabetes company”.
Also attending the ADA conference is Professor Jerry Palmer, Lead Investigator
for the Diamyd® Phase III trial in the US. Professor Palmer will chair a session
called “Type 1 Diabetes Prevention”.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB,
elisabeth.lindner@diamyd.com
Phone: +46-8-661 00 26
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB,
sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68
E-post: info@diamyd.com. VATno: SE556530-142001.
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials have been initiated in both the US and
Europe. Furthermore the company has initiated clinical studies within chronic
pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has
also out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com.
